Sibel Dosler1, A Alev Gerceker. 1. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Turkey. sibeldosler@hotmail.com
Abstract
BACKGROUND: We investigated the in vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant (MRSA) and -susceptible Staphylococcus aureus (MSSA) strains. METHODS: The minimum inhibitory concentrations were determined by microbroth dilution technique. Antibiotic combinations were assessed using the checkerboard technique. The time-kill curve method was used for determining the bactericidal activity of nisin alone and in combination. RESULTS: For both MSSA and MRSA strains, the minimum inhibitory concentrations of nisin ranged between 4 and 16 mg/l. With a fractional inhibitory concentration of ≥0.5 as borderline, synergistic interactions were seen in three of five isolates with nisin-ciprofloxacin compared to two of five isolates with nisin-vancomycin combinations against both MSSA and MRSA. No antagonism was observed. The results of time-kill curve analysis demonstrated concentration-dependent rapid bactericidal activity of nisin and synergism almost in all strains when nisin was used in combination with ciprofloxacin, and early synergistic interactions in some of the strains when it was used in combination with vancomycin. CONCLUSION: Nisin seems to be a good candidate for further investigations in the treatment of Gram-positive bacteria, alone or in combination with antibiotics.
BACKGROUND: We investigated the in vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant (MRSA) and -susceptible Staphylococcus aureus (MSSA) strains. METHODS: The minimum inhibitory concentrations were determined by microbroth dilution technique. Antibiotic combinations were assessed using the checkerboard technique. The time-kill curve method was used for determining the bactericidal activity of nisin alone and in combination. RESULTS: For both MSSA and MRSA strains, the minimum inhibitory concentrations of nisin ranged between 4 and 16 mg/l. With a fractional inhibitory concentration of ≥0.5 as borderline, synergistic interactions were seen in three of five isolates with nisin-ciprofloxacin compared to two of five isolates with nisin-vancomycin combinations against both MSSA and MRSA. No antagonism was observed. The results of time-kill curve analysis demonstrated concentration-dependent rapid bactericidal activity of nisin and synergism almost in all strains when nisin was used in combination with ciprofloxacin, and early synergistic interactions in some of the strains when it was used in combination with vancomycin. CONCLUSION: Nisin seems to be a good candidate for further investigations in the treatment of Gram-positive bacteria, alone or in combination with antibiotics.
Authors: J Keaton Smith; Abteen R Moshref; Jessica A Jennings; Harry S Courtney; Warren O Haggard Journal: Clin Orthop Relat Res Date: 2013-04-20 Impact factor: 4.176
Authors: Cleriane Andre; Natan de Jesus Pimentel-Filho; Paulo Mafra de Almeida Costa; Maria Cristina Dantas Vanetti Journal: Braz J Microbiol Date: 2019-08-27 Impact factor: 2.476
Authors: Des Field; Noémie Gaudin; Francy Lyons; Paula M O'Connor; Paul D Cotter; Colin Hill; R Paul Ross Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240
Authors: Thomas T Thomsen; Biljana Mojsoska; João C S Cruz; Stefano Donadio; Håvard Jenssen; Anders Løbner-Olesen; Kim Rewitz Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191